Blueprint’s latest approval for Ayvakit sets up clash with NovartisBlueprint Medicines has claimed its second FDA approval for Ayvakit, getting the nod for advanced systemic mastocytosis (SM), Share XBlueprint’s latest approval for Ayvakit sets up clash with Novartishttps://pharmaphorum.com/news/blueprints-latest-approval-for-ayvakit-sets-up-clash-with-novartis/
Roche, Blueprint raise pressure on Lilly with new Gavreto approvalThe FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting Share XRoche, Blueprint raise pressure on Lilly with new Gavreto approvalhttps://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/
Blueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drugCancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that Share XBlueprint and Roche take on Lilly as FDA approves RET-targeting lung cancer drughttps://pharmaphorum.com/news/blueprint-and-roche-take-on-lilly-as-fda-approves-ret-targeting-lung-cancer-drug/
European regulators back Blueprint’s Ayvakyt for stomach tumoursEuropean regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain Share XEuropean regulators back Blueprint’s Ayvakyt for stomach tumourshttps://pharmaphorum.com/news/european-regulators-back-blueprints-ayvakyt-for-stomach-tumours/
Roche signs $1.7bn deal with Blueprint around cancer drug pralsetinibRoche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that Share XRoche signs $1.7bn deal with Blueprint around cancer drug pralsetinibhttps://pharmaphorum.com/news/roche-signs-1-7bn-deal-with-blueprint-around-cancer-drug-pralsetinib/
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug The FDA has turned down Blueprint Medicines’ Ayvakit for more general use in gastrointestinal stromal tumour – Share XBlueprint pays the price of Ayvakit phase 3 miss as FDA rejects drughttps://pharmaphorum.com/news/blueprint-pays-the-price-of-ayvakits-phase-3-miss-as-fda-rejects-drug/
FDA clears Lilly’s Retevmo for RET-positive lung, thyroid cancersEli Lilly now has a second approved drug from its takeover of Loxo Oncology last year after getting Share XFDA clears Lilly’s Retevmo for RET-positive lung, thyroid cancershttps://pharmaphorum.com/news/fda-clears-lillys-retevmo-for-ret-positive-lung-thyroid-cancers/
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinibEli Lilly says it is eyeing an FDA verdict for RET-positive tumour treatment selpercatinib in the third quarter Share XLilly keeps ahead of Blueprint with swift FDA review for selpercatinibhttps://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535mIpsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a Share XIpsen adds Blueprint’s FOP rare disease drug to pipeline for $535mhttps://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
